Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395
admin@pathologynews.com2024-05-28T09:34:21+00:00Owkin, the first end-to-end TechBio unicorn that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, has unveiled an innovative drug pipeline in oncology and immunology following an exclusive global licensing agreement with Idorsia (SIX: IDIA) to develop and commercialize OKN4395, a clinic-ready best-in-class dual inhibitor of prostanoid receptors EP2 and EP4.










